Liquidia CorpLQDA
LQDA
About: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Employees: 170
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
31% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 49
29% more capital invested
Capital invested by funds: $625M [Q4 2024] → $808M (+$183M) [Q1 2025]
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
14% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 8 (+1) [Q1 2025]
3.39% more ownership
Funds ownership: 60.76% [Q4 2024] → 64.15% (+3.39%) [Q1 2025]
2% more funds holding
Funds holding: 164 [Q4 2024] → 167 (+3) [Q1 2025]
4% more call options, than puts
Call options by funds: $7.13M | Put options by funds: $6.87M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
8%
downside
Avg. target
$28
97%
upside
High target
$37
162%
upside
7 analyst ratings
6 positive
86%
0 neutral
0%
1 negative
14%
Wells Fargo Tiago Fauth | 77%upside $25 | Overweight Maintained | 12 Jun 2025 |
B of A Securities Jason Gerberry | 63%upside $23 | Buy Maintained | 11 Jun 2025 |
Needham Serge Belanger | 127%upside $32 | Buy Maintained | 2 Jun 2025 |
Scotiabank Greg Harrison | 162%upside $37 | Sector Outperform Maintained | 28 May 2025 |
HC Wainwright & Co. Andrew Fein | 148%upside $35 | Buy Maintained | 28 May 2025 |
Financial journalist opinion
Based on 4 articles about LQDA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Positive
Benzinga
2 weeks ago
These Analysts Boost Their Forecasts On Liquidia
On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's LQDA Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability.
Neutral
GlobeNewsWire
2 weeks ago
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company's Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday June 4, 2025, beginning at 11:05 a.m. ET, in New York City. Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation will be available on Liquidia's website for at least 30 days following the event. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Neutral
GlobeNewsWire
3 weeks ago
U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA™ (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA is the first and only prostacyclin dry-powder formulation enabled by Liquidia's proprietary PRINT™ technology, which yields uniform, free-flowing particles designed to enhance deep-lung delivery via an easy-to-use, low-effort device requiring less inspiratory effort.
Neutral
GlobeNewsWire
1 month ago
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368) against Liquidia alleging infringement of U.S. Patent No. 11,357,782 (the ‘782 patent). Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA™ (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Neutral
Seeking Alpha
1 month ago
Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Michael Kaseta - Chief Operating Officer and Chief Financial Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG, LLC Kambiz Yazdi - Jefferies Group LLC Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Serge Belanger - Needham & Company, LLC Ryan Deschner - Raymond James Financial, Inc. Operator Good morning, and welcome everyone to the Liquidia Corporation First Quarter 2025 Financial Results and Corporate Update Conference Call. My name is Ari, and I will be your conference operator today.
Negative
Zacks Investment Research
1 month ago
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.54 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will also host a webcast at 8:30 a.m. ET on May 8, 2025 to discuss its financial results and provide a corporate update.
Positive
Seeking Alpha
1 month ago
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month
Liquidia Corporation's legal victory clears the path for Yutrepia's FDA approval and market entry, targeting PAH and PH-ILD, with final approval expected by May 24, 2025. Yutrepia's competitive advantages include a patient-friendly inhaler, lower cost structure, and strong clinical profile, positioning it to capture market share from United Therapeutics' Tyvaso DPI. Liquidia is financially prepared for Yutrepia's launch, boasting $176.5 million in cash and milestone financing, ensuring a smooth commercialization without diluting shareholders.
Positive
Zacks Investment Research
1 month ago
Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Charts implemented using Lightweight Charts™